Category Archives: Cancer and neoplasms

Cancer and neoplasms

Next Generation Cologuard Outperforms FIT for CRC Detection, Shows Improved Sensitivity, Specificity

Posted on by yun
23
Oct

A next generation, noninvasive multitarget stool DNA (mt-sDNA) test was significantly more likely to detect cancerous or precancerous lesions than the standard fecal immunochemical test (FIT), according to study findings presented at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting in Vancouver, BC. The results, released during a late-breaking abstract session, showed the […]

Continue reading →
Cancer and neoplasms

The Changing Market Landscape of Benign Soft Tissue Sarcomas: Tenosynovial Giant Cell Tumors (TGCTs), Perivascular Epithelioid Cell Neoplasm (PEComa), Neurofibroma, and Vestibular Schwannoma | Key Insights and Findings by DelveInsight

Posted on by yun

Soft tissue sarcomas can impact people of all genders, ages, and diverse racial and ethnic backgrounds. While they encompass a wide range of tumor types, they remain relatively rare. The prevalence of soft tissue sarcomas varies, with the American Cancer Society approximating that they make up approximately 2% of all cancer cases, and around 13K […]

Continue reading →
Cancer and neoplasms

Relugolix Wins Approval in Canada for Advanced Prostate Cancer

Posted on by yun
23
Oct

Fred Saad, MD, FRCS Health Canada has approved the oral gonadotropin-releasing hormone receptor antagonist relugolix (Orgovyx) for the treatment of men with advanced prostate cancer, according to an announcement from Sumitomo Pharma.1 The regulatory decision was supported by data from the phase 3 HERO trial (NCT03085095). Findings showed that of patients treated with relugolix (n […]

Continue reading →
Cancer and neoplasms

TROPION-Breast01, TROPION-Lung01 Demonstrate PFS Benefit of Datopotamab Deruxtecan in Metastatic Breast Cancer, NSCLC

Posted on by yun
23
Oct

In both non–small cell lung cancer (NSCLC) and in hormone receptor–positive (HR+)/HER2-negative (HER2–) breast cancer, datopotamab deruxtecan demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared with standard of care. The results of TROPION-Breast01 and TROPION-Lung01 were presented at ESMO Congress 2023, held October 20-24, 2023, virtually and in person in Madrid, […]

Continue reading →
Cancer and neoplasms

New Research from Foundation Medicine and Roche Demonstrates Improved Outcomes Following Treatment Based on Comprehensive Genomic Profiling in Patients with Cancer of Unknown Primary Origin (CUP)

Posted on by yun
23
Oct

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct 20, 2023– Foundation Medicine Inc. and Roche today announced that they will present the results from a randomized, global precision oncology study designed to prospectively assess the efficacy and safety of molecularly-guided therapy for patients with unfavorable subset cancer of unknown primary (CUP). The results will be presented as a late breaking […]

Continue reading →
Cancer and neoplasms

Foundation Medicine Expands Partnership with Sequanta to Provide both Liquid and Tissue Genomic Profiling Services in China to Support Global Regulatory Filings

Posted on by yun
23
Oct

CAMBRIDGE, Mass. & SHANGHAI–(BUSINESS WIRE)– Foundation Medicine, Inc., today announced that it has expanded its partnership with Sequanta Technologies Co., Ltd. (“Sequanta”) to provide genomic profiling services to support clinical research and the development of oncology therapies in China. Foundation Medicine has a long-standing partnership with Sequanta as its in-house laboratory in China since 2014 […]

Continue reading →
Cancer and neoplasms

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

Posted on by yun
23
Oct

Abstract The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid tumors, and could be a promising treatment target. We report dose escalation results from the ongoing phase 1/2 BNT211-01 trial evaluating the safety and feasibility of chimeric antigen receptor (CAR) T cells targeting the CLDN6 with or without a CAR-T […]

Continue reading →
Cancer and neoplasms

Trastuzumab Deruxtecan Demonstrates Efficacy Reducing Brain Metastases in HER2m NSCLC

Posted on by yun
22
Oct

In patients with metastatic HER2 (ERBB2)-mutant (HER2m) non­–small cell lung cancer (NSCLC), the presence of brain metastases (BM) did not affect response to treatment with trastuzumab deruxtecan, according to results presented at ESMO Congress 2023, held October 20-24, both virtually and in Madrid, Spain. David Planchard, MD, PhD Image credit: ESMO Approximately one-fifth of patients […]

Continue reading →